G-protein coupled receptors of the renin-angiotensin system: New targets against breast cancer?

Frontiers in Pharmacology

Volumn 6, Issue FEB, 2015, Pages

  Rodrigues Ferreira, Sylvie ^a   Nahmias, Clara ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Angiotensin; ARBs; Breast cancer; GPCR; Mas; Therapy

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; ANTINEOPLASTIC AGENT; AZILSARTAN; BEVACIZUMAB; C 21; CANDESARTAN; CGEN 856; DIPEPTIDYL CARBOXYPEPTIDASE; EMA 401; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPROSARTAN; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; IRBESARTAN; LOSARTAN; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; OLMESARTAN; TAMOXIFEN; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; COLORECTAL LIVER METASTASIS; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESPONSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HYPERTENSION; IN SITU HYBRIDIZATION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG METASTASIS; MACROPHAGE; METASTASIS; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SIGNAL TRANSDUCTION; SOFT TISSUE CANCER; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

EID: 84926490139     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00024     Document Type: Short Survey

References (78)

1. Ager, E. I., Chong, W. W., Wen, S. W., and Christophi, C. (2010). Targeting the angiotensin II type 2 receptor (AT2R) in colorectal liver metastases. Cancer Cell Int. 10, 19-30. doi: 10.1186/1475-2867-10-19
2. ARB Trialists Collaboration. (2011). Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J. Hypertens. 29, 623-635. doi: 10.1097/HJH.0b013e328344a7de
3. Arrieta, O., Pineda-Olvera, B., Guevara-Salazar, P., Hernández-Pedro, N., Morales-Espinosa, D., Cerón-Lizarraga, T. L.,et al. (2008). Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. Br. J. Cancer 99, 160-166. doi: 10.1038/sj.bjc.6604431
4. Azoulay, L., Assimes, T. L., Yin, H., Bartels, D. B., Schiffrin, E. L., and Suissa, S. (2012). Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS ONE 7:e50893. doi: 10.1371/journal.pone.0050893
5. Bader, M., Santos, R. A., Unger, T., and Steckelings, U. M. (2012). New therapeutic pathways in the RAS. J. Renin Angiotensin Aldosterone Syst. 13, 505-508. doi: 10.1177/1470320312466519
6. Bhaskaran, K., Douglas, I., Evans, S., Van Staa, T., and Smeeth, L. (2012). Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ. 344, e2697. doi: 10.1136/bmj.e2697
7. Cardwell, C. R., Mc Menamin, ú. C., Hicks, B. M., Hughes, C., Cantwell, M. M., Murray, L. J. (2014). Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal, and prostate cancer patient cohorts. BMC Med. 12:28. doi: 10.1186/1741-7015-12-28
8. Chae, Y. K., Brown, E. N., Lei, X., Melhem-Bertrandt, A., Giordano, S. H., Litton, J. K.,et al. (2013). Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J. Cancer 4, 549-556. doi: 10.7150/jca.6888
9. Chae, Y. K., Valsecchi, M. E., Kim, J., Bianchi, A. L., Khemasuwan, D., Desai, A.,et al. (2011). Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest. 29, 585-593. doi: 10.3109/07357907.2011.616252
10. Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., and Kozin, S. V.,et al. (2013). Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4, 2516. doi: 10.1038/ncomms3516
11. Chen, X., Meng, Q., Zhao, Y., Liu, M., Li, D., Yang, Y.,et al. (2013). Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett. 328, 318-324. doi: 10.1016/j.canlet.2012.10.006
12. Clere, N., Corre, I., Faure, S., Guihot, A. L., Vessières, E., Chalopin, M.,et al. (2010). Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int. J. Cancer 127, 2279-2291. doi: 10.1002/ijc.25234
13. Cook, K. L., Metheny-Barlow, L. J., Tallant, E. A., and Gallagher, P. E. (2010). Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res. 70, 8319-8328. doi: 10.1158/0008-5472.CAN-10-1136
14. Crowley, S. D., and Coffman, T. M. (2012). Recent advances involving the renin-angiotensin system. Exp. Cell Res. 318, 1049-1056. doi: 10.1016/j.yexcr.2012.02.023
15. De Paepe, B., Verstraeten, V. L., De Potter, C. R., Vakaet, L. A., and Bullock, G. R. (2001). Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem. Cell Biol. 116, 247-254. doi: 10.1007/s004180100313
16. De Paepe, B., Verstraeten, V. M., De Potter, C. R., and Bullock, G. R. (2002). Increased angiotensin II type-2 receptor density in hyperplasia, DCIS, and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem. Cell Biol. 117, 13-19. doi: 10.1007/s00418-001-0356-0
17. de Ronde, J. J., Lips, E. H., Mulder, L., Vincent, A. D., Wesseling, J., Nieuwland, M.,et al. (2013). SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Res. Treat. 137, 213-223. doi: 10.1007/s10549-012-2340-x
18. Deshayes, F., and Nahmias, C. (2005). Angiotensin II receptors: a new role in cancer? Trends Endocrinol. Metab. 16, 293-299. doi: 10.1016/j.tem.2005.07.009
19. Ding, X., Zhang, N., Cai, Y., Li, S., Zheng, C., Jin, Y., et al. (2012). Down-regulation of tumor suppressor MTUS1/ATIP is associated with enhanced proliferation, poor differentiation, and poor prognosis in oral tongue squamous cell carcinoma. Mol. Oncol. 6, 73-80. doi: 10.1016/j.molonc.2011.11.002
20. Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., and Jain, R. K. (2011). Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. U.S.A. 108, 2909-2914. doi: 10.1073/pnas.1018892108
21. Doi, C., Egashira, N., Kawabata, A., Maurya, D. K., Ohta, N., Uppalapati, D.,et al. (2010). Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer 10:67. doi: 10.1186/1471-2407-10-67
22. Egami, K., Murohara, T., Shimada, T., Sasaki, K., Shintani, S., Sugaya, T.,et al. (2003). Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest. 112, 67-75. doi: 10.1172/JCI16645
23. Ferreira, A. J., Bader, M., and Santos, R. A. (2012). Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review. Expert Opin. Ther. Pat. 22, 567-574. doi: 10.1517/13543776.2012.682572
24. Fryzek, J. P., Poulsen, A. H., Lipworth, L., Pedersen, L., Nørgaard, M., McLaughlin, J. K.,et al. (2006). A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res. Treat. 97, 231-236. doi: 10.1007/s10549-005-9091-x
25. Fujita, M., Hayashi, I., Yamashina, S., Fukamizu, A., Itoman, M., and Majima, M. (2005). Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26, 271-279. doi: 10.1093/carcin/bgh324
26. Gallagher, P. E., and Tallant, E. A. (2004). Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 25, 2045-2052. doi: 10.1093/carcin/bgh236
27. Gampenrieder, S. P., Romeder, F., Mub, C., Pircher, M., Ressler, S., Rinnerthaler, G.,et al. (2014). Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis. Anticancer. Res. 34, 227-233.
28. George, A. J., Thomas, W. G., and Hannan, R. D. (2010). The renin-angiotensin system and cancer: old dog, new tricks. Nat. Rev. Cancer 10, 745-759. doi: 10.1038/nrc2945
29. Harmer, D., Gilbert, M., Borman, R., and Clark, K. L. (2002). Quantitative mRNA expression profiling of ACE 2, a novel homologe of angiotensin converting enzyme. FEBS Lett. 532, 107-110. doi: 10.1016/S0014-5793(02)03640-2
30. Herr, D., Rodewald, M., Fraser, H. M., Hack, G., Konrad, R., Kreienberg, R.,et al. (2008). Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol. Oncol. 109, 418-425. doi: 10.1016/j.ygyno.2008.02.019
31. Imai, N., Hashimoto, T., Kihara, M., Yoshida, S., Kawana, I., Yazawa, T.,et al. (2007). Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab. Invest. 87, 189-198. doi: 10.1038/labinvest.3700504
32. Inwang, E. R., Puddefoot, J. R., Brown, C. L., Goode, A. W., Marsigliante, S., Ho, M. M.,et al. (1997). Angiotensin II type 1 receptor expression in human breast tissues. Br. J. Cancer 75, 1279-1283. doi: 10.1038/bjc.1997.217
33. Iwai, M., Nakaoka, H., Senba, I., Kanno, H., Moritani, T., and Horiuchi, M. (2012). Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling. Hypertension 60, 137-144. doi: 10.1161/HYPERTENSIONAHA.112.191452
34. Kawabata, A., Baoum, A., Ohta, N., Jacquez, S., Seo, G. M., Berkland, C.,et al. (2012). Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth. Cancer Res. 72, 2057-2067. doi: 10.1158/0008-5472.CAN-11-3634
35. Krishnan, B., Torti, F. M., Gallagher, P. E., and Tallant, E. A. (2013a). Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate 73, 60-70. doi: 10.1002/pros.22540
36. Krishnan, B., Smith, T. L., Dubey, P., Zapadka, M. E., Torti, F. M., Willingham, M. C., et al. (2013b). Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate 73, 71-82. doi: 10.1002/pros.22542
37. Li, C. I., Daling, J. R., Tang, M. T., Haugen, K. L., Porter, P. L., Malone, K. E. (2013). Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern. Med. 173, 1629-1637. doi: 10.1001/jamainternmed.2013.9071
38. Li, C. I., Malone, K. E., Weiss, N. S., Boudreau, D. M., Cushing-Haugen, K. L., and Daling, J. R. (2003). Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 98, 1504-1513. doi: 10.1002/cncr.11663
39. Machado, R. D., Santos, R. A., and Andrade, S. P. (2001). Mechanisms of angiotensin-(1-7)-induced inhibition of angiogenesis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280, R994-R1000.
40. McCarthy, C. A., Widdop, R. E., Denton, K. M., and Jones, E. S. (2013). Update on the angiotensin AT(2) receptor. Curr. Hypertens. Rep. 15, 25-30. doi: 10.1007/s11906-012-0321-4
41. Mc Menamin, ú. C., Murray, L. J., Cantwell, M. M., and Hughes, C. M. (2012). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control 23, 221-230. doi: 10.1007/s10552-011-9881-x
42. Menon, J., Soto-Pantoja, D. R., Callahan, M. F., Cline, J. M., Ferrario, C. M., Tallant, E. A.,et al. (2007). Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res. 67, 2809-2815. doi: 10.1158/0008-5472.CAN-06-3614
43. Miller, N., McCann, A. H., O'Connell, D., Pedersen, I. S., Spiers, V., Gorey, T.,et al. (1997). The MAS proto-oncogene is imprinted in human breast tissue. Genomics 46, 509-512. doi: 10.1006/geno.1997.5063
44. Miyajima, A., Kosaka, T., Asano, T., Asano, T., Seta, K., Kawai, T.,et al. (2002). Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 62, 4176-4179.
45. Namazi, S., Rostami-Yalmeh, J., Sahebi, E., Jaberipour, M., Razmkhah, M., and Hosseini, A. (2014a). The role of captopril and losartan in prevention and regression of tamoxifen-induced resistance of breast cancer cell line MCF-7: an in vitro study. Biomed. Pharmacother. 68, 565-571. doi: 10.1016/j.biopha.2014.05.004
46. Namazi, S., Sahebi, E., Rostami-Yalmeh, J., Jaberipour, M., Razmkhah, M., Hosseini, A., et al. (2014b). Effect of angiotensin receptor blockade on prevention and reversion of tamoxifen-resistant phenotype in MCF-7 cells. Tumour Biol. doi: 10.1007/s13277-014-2713-3 [Epub ahead of print].
47. Passos-Silva, D. G., Verano-Braga, T., and Santos, R. A. (2013). Angiotensin-(1-7): beyond the cardio-renal actions. Clin. Sci. (Lond.). 124, 443-456. doi: 10.1042/CS20120461
48. Petty, W. J., Miller, A. A., McCoy, T. P., Gallagher, P. E., Tallant, E. A., and Torti, F. M. (2009). Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin. Cancer Res. 15, 7398-7404. doi: 10.1158/1078-0432.CCR-09-1957
49. Pickel, L., Matsuzuka, T., Doi, C., Ayuzawa, R., Maurya, D. K., Xie, S. X.,et al. (2010). Overexpression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. Cancer Biol. Ther. 9, 277-285. doi: 10.4161/cbt.9.4.10643
50. Pils, D., Horak, P., Gleiss, A., Sax, C., Fabjani, G., and Moebus, V. J.,et al. (2005). Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer 104, 2417-2429. doi: 10.1002/cncr.21538
51. Pham, H., Schwartz, B. M., Delmore, J. E., Reed, E., Cruickshank, S., Drummond, L.,et al. (2013). Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy. Cancer Chemother. Pharmacol. 71, 965-972. doi: 10.1007/s00280-013-2089-x
52. Porrello, E. R., Delbridge, L. M., and Thomas, W. G. (2009). The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front. Biosci. (Landmark Ed). 14:972. doi: 10.2741/3289
53. Rhodes, D. R., Ateeq, B., Cao, Q., Tomlins, S. A., Mehra, R., Laxman, B.,et al. (2009). AGTR1 overexpression defines a subset of breast cancerand confers sensitivity to losartan, an AGTR1 antagonist. Proc. Natl. Acad. Sci. U.S.A. 106, 10284-10289. doi: 10.1073/pnas.0900351106
54. Rice, A. S., Dworkin, R. H., McCarthy, T. D., Anand, P., Bountra, C., McCloud, P. I.,et al. (2014). EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 383, 1637-1647. doi: 10.1016/S0140-6736(13)62337-5
55. Rodgers, K. E., Oliver, J., and Di Zerega, G. S. (2006). Phase I/II dose escalation study of angiotensin 1-7 [A (1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother. Pharmacol. 57, 559-568. doi: 10.1007/s00280-005-0078-4
56. Rodrigues-Ferreira, S., Abdelkarim, M., Dillenburg-Pilla, P., Luissint, A. C., Di-Tommaso, A., Deshayes, F., et al. (2012a). Angiotensin II facilitates breast cancer cell migration and metastasis. PLoS ONE 7:e35667-e35674. doi: 10.1371/journal.pone.0035667
57. Rodrigues-Ferreira, S., Morel, M., Reis, R. I., Cormier, F., Baud, V., Costa-Neto, C. M., et al. (2012b). A novel cellular model to study angiotensin ii at2 receptor function in breast cancer cells. Int. J. Peptides 2012, 1-6. doi: 10.1155/2012/745027
58. Rodrigues-Ferreira, S., Di Tommaso, A., Dimitrov, A., Cazaubon, S., Gruel, N., Colasson, H.,et al. (2009). 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. PLoS ONE 4:e7239. doi: 10.1371/journal.pone.0007239
59. Rodrigues-Ferreira, S., Molina, A., Nehlig, A., Nahmias, C. (2015). "The AT2 receptor and interacting proteins ATIPs in cancer," in The Protective Arm of the Renin Angiotensin System (RAS): Functional Aspects and Therapeutic Implications, eds T. Unger, U. M. Steckelings, and R. A. Santos (Amsterdam: Elsevier Press).
60. Rosenthal, T., and Gavras, I. (2009). Angiotensin inhibition and malignancies: a review. J. Hum. Hypertens. 23, 623-635. doi: 10.1038/jhh.2009.21
61. Salvador, J., Manso, L., De La Haba, J., Jaen, A., Ciruelos, E., de Villena, M. C., et al. (2014). Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clin. Transl. Oncol. doi: 10.1007/s10549-010-1002-0 [Epub ahead of print].
62. Sánchez-Rovira, P., Seguí, M. A., Llombart, A., Aranda, E., Antón, A., Sánchez, A., et al. (2013). Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response. Clin. Transl. Oncol. 15, 810-817. doi: 10.1007/s12094-013-1006-4
63. Santos, R. A., Ferreira, A. J., Verano-Braga, T., and Bader, M. (2013). Angiotensin-converting enzyme 2, Angiotensin-(1-7) and Mas: new players of the Renin Angiotensin System. J. Endocrinol. 216, R1-R17. doi: 10.1530/JOE-12-0341
64. Santos, R. A., Simoese Silva, A. C., Maric, C., Silva, D. M., Machado, R. P., de Buhr, I.,et al. (2003). Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100, 8258-8263. doi: 10.1073/pnas.1432869100
65. Seibold, S., Rudroff, C., Weber, M., Galle, J., Wanner, C., and Marx, M. (2003). Identification of a new tumor suppressor gene located at chromosome 8p21.3-22. FASEB J. 17, 1180-1182.
66. Sipahi, I., Debanne, S. M., Rowland, D. Y., Simon, D. I., and Fang, J. C. (2010). Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 11, 627-636. doi: 10.1016/S1470-2045(10)70106-6
67. Sørensen, G. V., Ganz, P. A., Cole, S. W., Pedersen, L. A., Sørensen, H. T., Cronin-Fenton, D. P., et al. (2012). Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J. Clin. Oncol. 31, 2265-2272. doi: 10.1200/JCO.2012.43.9190
68. Soto-Pantoja, D. R., Menon, J., Gallagher, P. E., and Tallant, E. A. (2009). Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol. Cancer Ther. 8, 1676-1683. doi: 10.1158/1535-7163.MCT-09-0161
69. Steckelings, U. M., Larhed., M., Hallberg, A., Widdop, R. E., Jones, E. S., Wallinder, C.,et al. (2011). Non-peptide AT2-receptor agonists. Curr. Opin. Pharmacol. 11, 187-192. doi: 10.1016/j.coph.2010.11.002
70. Tahmasebi, M., Barker, S., Puddefoot, J. R., and Vinson, G. P. (2006). Localisation of renin-angiotensin system (RAS) components in breast. Br. J. Cancer 95, 67-74. doi: 10.1038/sj.bjc.6603213
71. Tallant, E. A., and Gallagher, P. E. (2014). Angiotensin-(1-7) As a Chemoprevention Agent. Patent number: 20140296143.
72. Tallant, E. A., Gallagher, P. E., and Ferrario, C. M. (2011). Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth. Patent number: 8034781. doi: 10.1111/j.1476-5381.2012.01905.x
73. Thakur, A., and Witteles, R. M. (2014). Cancer therapy-induced left ventricular dysfunction: interventions and prognosis. J. Card. Fail. 20, 155-158. doi: 10.1016/j.cardfail.2013.12.018
74. Unger, T., and Dahlöf, B. (2010). Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential. J. Renin Angiotensin Aldosterone Syst. 11, 75-77. doi: 10.1177/1470320309347792
75. Wagenaar, G. T., Laghmani, El H., Fidder, M., Sengers, R. M., De Visser, Y. P., De Vries, L.,et al. (2013). Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats withneonatal hyperoxia-induced lung injury. Am. J. Physiol. Lung. Cell Mol. Physiol. 305, L341-L351. doi: 10.1152/ajplung.00360.2012
76. Xiao, J., Chen, J. X., Zhu, Y. P., Zhou, L. Y., Shu, Q. A., and Chen, L. W. (2012). Reduced expression of MTUS1 mRNA is correlated with poor prognosis in bladder cancer. Oncol. Lett. 4, 113-118.
77. Ye, H., Pungpravat, N., Huang, B. L., Muzio, L. L., Mariggiò, M. A., Chen, Z.,et al. (2007). Genomic assessments of the frequent loss of heterozygosity region on 8p21.3-8p22 in head and neck squamous cell carcinoma. Cancer Genet. Cytogenet. 176, 100-106. doi: 10.1016/j.cancergencyto.2007.04.003
78. Zuern, C., Heimrich, J., Kaufmann, R., Richter, K. K., Settmacher, U., Wanner, C.,et al. (2010) Down-regulation of MTUS1 in human colon tumors. Oncol. Rep. 23, 183-189.